First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology

BACKGROUND: Immunotherapy represents the standard of care in the first-line treatment of advanced non-small-cell lung cancer (NSCLC), either as monotherapy in high programmed death-ligand 1 (PD-L1)-positive tumors (≥50%) or in combination with platinum-based chemotherapy regardless of PD-L1 status....

Descripción completa

Detalles Bibliográficos
Autores principales: Gridelli, C., Peters, S., Mok, T., Forde, P.M., Reck, M., Attili, I., de Marinis, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8689080/
https://www.ncbi.nlm.nih.gov/pubmed/34922299
http://dx.doi.org/10.1016/j.esmoop.2021.100355

Ejemplares similares

Ejemplares similares